Letko, Brosseau & Associates’s Aldeyra Therapeutics ALDX Stock Holding History

Letko, Brosseau & Associates’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$21.3K	Hold	17,300	–	–	﹤0.01%	107
2026 Q2	$36.8K	Hold	17,300	–	–	﹤0.01%	110
2026 Q1	$29.2K	Hold	17,300	–	–	﹤0.01%	98
2025 Q4	$89.6K	Hold	17,300	–	–	﹤0.01%	98
2025 Q3	$90.3K	Hold	17,300	–	–	﹤0.01%	95
2025 Q2	$66.3K	Hold	17,300	–	–	﹤0.01%	93
2025 Q1	$99.5K	Hold	17,300	–	–	﹤0.01%	85
2024 Q4	$86.3K	Buy	+17,300	New	+$88.8K	﹤0.01%	97

Other funds holding ALDX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Savant Capital Rockford, Illinois $35B AUM 15.18% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 22.25% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Providence Wealth Advisors Frankfort, Illinois $174M AUM 29.13% 1-Year Est. Return

Hikari Power Tokyo, Japan $439M AUM 11.38% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Letko, Brosseau & Associates's ALDX Position: Q3 2026 in Review

Letko, Brosseau & Associates held its Aldeyra Therapeutics (ALDX) position steady in Q3 2026 at 17,300 shares worth $21.3K. The position accounts for ﹤0.01% of the portfolio, ranked #107.

Letko, Brosseau & Associates first reported a position in ALDX in Q4 2024 and has held it in 8 quarters since. The position peaked at $99.5K in Q1 2025. 28 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

Letko, Brosseau & Associates held 17,300 shares of Aldeyra Therapeutics worth $21.3K as of Q3 2026.
Letko, Brosseau & Associates left its Aldeyra Therapeutics share count unchanged in Q3 2026.
Aldeyra Therapeutics made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q3 2026, its #107 holding.
Letko, Brosseau & Associates first reported a position in Aldeyra Therapeutics in Q4 2024 and has held it in 8 quarters since.
Letko, Brosseau & Associates's Aldeyra Therapeutics position peaked at $99.5K in Q1 2025.
28 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q3 2026, filed 6 Nov 2026.